Financing ·
Tango Therapeutics raises $566.5 million in underwritten offering of common stock and pre-funded warrants
TNGXTango Therapeutics, Inc.
Tango Therapeutics, Inc. entered into an underwriting agreement on June 9, 2026, to conduct an underwritten offering of 18,166,667 shares of common stock at $30.00 per share and 1,833,395 pre-funded warrants at $29.999 per warrant. The offering includes a 30-day option for underwriters to purchase up to 3,000,009 additional shares. The company expects net proceeds of approximately $566.5 million, which it intends to use for research and development, pivotal trial expenses, and general corporate purposes. Management believes these funds will extend its operating runway into 2030. Tango Therapeutics is a biotechnology company focused on developing precision medicines.